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A new animal model to study sudden cardiac deathSudden cardiac death (SCD) is the most common cause of
cardiovascular-related death, accounting for more than 50% of
all cardiovascular mortality worldwide.1 SCD is often the first
manifestation of unrecognized cardiac disease.2 Ventricular
tachyarrhythmias, mainly ventricular fibrillation, are primarily
responsible for the mechanism underlying most SCD episodes.
Ventricular tachyarrhythmias occur frequently in the setting of
coronary artery disease with or without the presence of
myocardial infarction. In spite of the prevalence of defib-
rillation programs, and frequent attempts made to resuscitate
patients experiencing SCD, the survival rate after SCD was
substantially unsatisfactory.3 Most SCD episodes occur in
individuals without previously known cardiac disease, further
making the inability to successfully identify and properly treat
this disease a critical public health problem.
Ventricular fibrillation accounts for most of the deaths
occurring in the acute phase of ischemia (within hours to
days), whereas sustained, monomorphic ventricular tachy-
cardia due to reentry generated in the scar tissue usually
develops in the setting of a healed myocardial infarction
(typically weeks to months).4 There is a distinction in
arrhythmias occurring in the subacute phase of myocardial
infarction and in the chronic phase. The electrophysiological
mechanisms involved with arrhythmia generation and elec-
trical remodeling have been extensively studied.5 In addition,
SCD as the result of ventricular tachyarrhythmias is the most
ominous presentation of myocardial infarction. SCD in the
immediate period after myocardial infarction represents a
clinical challenge, particularly in patients with left ventricular
dysfunction or heart failure.6 It is now well established that
ventricular tachyarrhythmia in the setting of infarction is a
reentrant arrhythmia where cells in the infarct border have
normal action potentials but display slow and discontinuous
conduction, which is associated with abnormal connexin
expression.7 Furthermore, it has been noticed that only a
minority of patients who have been successfully resuscitated
from SCD associated with coronary artery disease sub-
sequently developed a myocardial infarction. The patho-
physiology and electrophysiology involved with reperfusion
arrhythmia and SCD are distinct from those in the setting of
ischemia and infarction.8
Beyond ischemia-reperfusion etiology, ventricular
tachyarrhythmia and SCD are attributed to genetic arrhythmia
syndromes and cardiomyopathies.1,9 Because such events are1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.06.014almost always catastrophic or fatal at presentation, it is
impossible to conduct complete human studies in elucidating
and exploring the mechanisms, including abnormal excit-
ability, conduction, or repolarization, and underlying molec-
ular or cellular biology leading to SCD. Our current
knowledge of arrhythmias stems from animal models serving
as surrogates for humans. Beyond mechanism studies, a stable
and reproducible animal model is helpful to evaluate novel
antiarrhythmic compounds and to study proarrhythmic effects
of both cardiac and noncardiac therapeutic agents.10
In this issue of the Journal, Dr. Chen and his colleagues
established a swine model of ischemic SCD.11 The middle
portion of the left anterior descending coronary artery was
blocked by the balloon catheter to control the infarction
area. Myocardial infarction was confirmed by electro-
cardiograms and pathological examinations, and ventricular
tachyarrhythmia and SCD were confirmed by continuous
electrocardiographic recordings. They successfully induced
ventricular fibrillation and SCD in 16 of 20 of their animals and
were unable to secure seven animals from recurrent ventricular
fibrillation. This closed-chest technique is less traumatic and
more similar to pathophysiology that occurs in humans during
ischemic insults compared with the open-chest ligation method.
In addition, the coronary characteristics and cardiac electro-
physiological properties in swine are similar in those of
humans.
Several points should be acknowledged. First, this swine
model is at best a simulation of the clinical phenotype. The
techniques used to establish myocardial infarction in this
model were different from the pathophysiology responsible for
myocardial infarction in most patients in the clinical setting.
Some information obtained from studies on nonprimate
mammals may not be extrapolated to humans. Second, the
study was conducted on anesthetized animals, which might
have differences in thresholds for ventricular arrhythmias. The
use of anesthetics in studying ventricular arrhythmias is con-
tentious, because some directly alter arrhythmogenicity and
others alter autonomic efferent traffic, which affects arrhyth-
mogenicity.10 Third, in the current model there was no elec-
trophysiology study to induce ventricular tachyarrhythmias in
the surviving animals. Fourth, the current model constructed in
the setting of ischemic myocardium is not applicable to non-
ischemic SCD, particularly cardiomyopathy and genetic
arrhythmia-related SCD.12hinese Medical Association. All rights reserved.
480 Editorial / Journal of the Chinese Medical Association 76 (2013) 479e480Death from ventricular arrhythmia remains an important
challenge in medicine. The animal models are necessary
because they allow for controlled studies and methods of
exploration that, for legal and ethical reasons, are not possible
in humans. A successful animal model mimicking human
structural and electrophysiological properties is important in
understanding the genesis of such a fatal condition, and is
essential in the development of therapeutic strategies.
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